JP2018521020A5 - - Google Patents

Download PDF

Info

Publication number
JP2018521020A5
JP2018521020A5 JP2017563311A JP2017563311A JP2018521020A5 JP 2018521020 A5 JP2018521020 A5 JP 2018521020A5 JP 2017563311 A JP2017563311 A JP 2017563311A JP 2017563311 A JP2017563311 A JP 2017563311A JP 2018521020 A5 JP2018521020 A5 JP 2018521020A5
Authority
JP
Japan
Prior art keywords
compound
following formula
pharmaceutically acceptable
acceptable salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017563311A
Other languages
English (en)
Other versions
JP6549735B2 (ja
JP2018521020A (ja
Filing date
Publication date
Priority claimed from PCT/IB2015/001693 external-priority patent/WO2016198908A1/en
Application filed filed Critical
Priority claimed from PCT/US2016/036283 external-priority patent/WO2016200851A1/en
Publication of JP2018521020A publication Critical patent/JP2018521020A/ja
Publication of JP2018521020A5 publication Critical patent/JP2018521020A5/ja
Application granted granted Critical
Publication of JP6549735B2 publication Critical patent/JP6549735B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (4)

  1. 以下の式:
    Figure 2018521020
    の化合物。
  2. 以下の式:
    Figure 2018521020
    の化合物の医薬として許容される塩である、化合物。
  3. 以下の式:
    Figure 2018521020
    の化合物。
  4. 以下の式:
    Figure 2018521020
    の化合物の医薬として許容される塩である、化合物。
JP2017563311A 2015-06-09 2016-06-08 核内受容体調節剤 Active JP6549735B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
PCT/IB2015/001693 WO2016198908A1 (en) 2015-06-09 2015-06-09 Ror nuclear receptor modulators
IBPCT/IB2015/001693 2015-06-09
US201562257806P 2015-11-20 2015-11-20
US62/257,806 2015-11-20
US201662343905P 2016-06-01 2016-06-01
US62/343,905 2016-06-01
PCT/US2016/036283 WO2016200851A1 (en) 2015-06-09 2016-06-08 Nuclear receptor modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019118167A Division JP2019178159A (ja) 2015-06-09 2019-06-26 核内受容体調節剤

Publications (3)

Publication Number Publication Date
JP2018521020A JP2018521020A (ja) 2018-08-02
JP2018521020A5 true JP2018521020A5 (ja) 2019-02-28
JP6549735B2 JP6549735B2 (ja) 2019-07-24

Family

ID=56194583

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017563311A Active JP6549735B2 (ja) 2015-06-09 2016-06-08 核内受容体調節剤
JP2019118167A Ceased JP2019178159A (ja) 2015-06-09 2019-06-26 核内受容体調節剤
JP2020135558A Active JP6938737B2 (ja) 2015-06-09 2020-08-11 核内受容体調節剤
JP2021140781A Active JP7235816B2 (ja) 2015-06-09 2021-08-31 核内受容体調節剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019118167A Ceased JP2019178159A (ja) 2015-06-09 2019-06-26 核内受容体調節剤
JP2020135558A Active JP6938737B2 (ja) 2015-06-09 2020-08-11 核内受容体調節剤
JP2021140781A Active JP7235816B2 (ja) 2015-06-09 2021-08-31 核内受容体調節剤

Country Status (37)

Country Link
US (4) US10106501B2 (ja)
EP (2) EP3636643A1 (ja)
JP (4) JP6549735B2 (ja)
KR (1) KR20180014433A (ja)
CN (1) CN107820494B (ja)
AU (3) AU2016276316B2 (ja)
BR (1) BR112017026452A2 (ja)
CA (1) CA2988502A1 (ja)
CL (1) CL2017003147A1 (ja)
CO (1) CO2017012594A2 (ja)
CR (1) CR20170594A (ja)
CY (1) CY1122495T1 (ja)
DK (1) DK3307734T3 (ja)
DO (1) DOP2017000289A (ja)
EC (1) ECSP18001225A (ja)
ES (1) ES2774517T3 (ja)
HK (1) HK1248678A1 (ja)
HR (1) HRP20200064T1 (ja)
HU (1) HUE047988T2 (ja)
IL (2) IL256043B (ja)
LT (1) LT3307734T (ja)
MA (1) MA51556A (ja)
MX (2) MX2017015980A (ja)
MY (1) MY193715A (ja)
PE (1) PE20230683A1 (ja)
PH (1) PH12017502237A1 (ja)
PL (1) PL3307734T3 (ja)
PT (1) PT3307734T (ja)
RS (1) RS59934B1 (ja)
RU (1) RU2715897C2 (ja)
SG (1) SG10201911849SA (ja)
SI (1) SI3307734T1 (ja)
TW (2) TW202128619A (ja)
UA (1) UA120651C2 (ja)
UY (1) UY36716A (ja)
WO (1) WO2016200851A1 (ja)
ZA (1) ZA201708285B (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3307734T (lt) * 2015-06-09 2020-05-11 Abbvie Inc. Branduolinio receptoriaus moduliatoriai (ror), skirti uždegiminių ir autoimuninių ligų gydymui
US10435403B2 (en) 2015-06-09 2019-10-08 Bayer Pharma Aktiengesellschaft Positive allosteric modulators of muscarinic M2 receptor
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
JP2019524722A (ja) 2016-07-11 2019-09-05 バイエル・ファルマ・アクティエンゲゼルシャフト 7−置換1−ピリジル−ナフチリジン−3−カルボン酸アミドおよびその使用
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
CN108689942B (zh) * 2017-04-11 2023-06-09 广东东阳光药业有限公司 含氮双环化合物及其制备方法和用途
US11427596B2 (en) * 2019-07-19 2022-08-30 Indian Institute of Technology Indore Metal-free solvent-free synthesis of fused-pyrido heterocycles and biomedical applications
CN110407863B (zh) * 2019-08-24 2021-08-17 中国科学院兰州化学物理研究所 一种通过转移硼化反应合成烯基硼酸酯类化合物的方法
CN110483561B (zh) * 2019-08-24 2021-07-23 中国科学院兰州化学物理研究所 一种烯基硼酸酯类化合物的合成方法
CN114436833A (zh) * 2021-12-27 2022-05-06 南京红太阳医药研究院有限公司 一种替米沙坦关键中间体4′-甲基联苯-2-羧酸酯的制备方法
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2091257A1 (en) 1990-09-10 1992-03-11 Fu-Chih Huang Substituted bicyclic aryl compounds exhibiting selective leukotriene b4 antagonists activity
US5290798A (en) 1991-09-30 1994-03-01 Merck Frosst Canada, Inc. (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
ZA928276B (en) 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
JP3457694B2 (ja) 1993-02-04 2003-10-20 第一製薬株式会社 インフルエンザ感染予防・治療薬
US5589482A (en) 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
US6124463A (en) 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
CA2430978C (en) 2000-12-28 2012-05-15 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
US20070129334A1 (en) 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
AU2003220896A1 (en) 2002-03-28 2003-11-10 Sumitomo Pharmaceuticals Co., Ltd. Novel heteroaryl compounds
AU2003297431A1 (en) 2002-12-20 2004-07-22 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
WO2004099192A2 (en) 2003-04-30 2004-11-18 The Institutes Of Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
KR101149379B1 (ko) 2003-07-28 2012-06-28 얀센 파마슈티카 엔.브이. 벤즈이미다졸, 벤즈티아졸 및 벤즈옥사졸 유도체 및lta4 h 조정자로서의 그의 용도
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US20080269284A1 (en) 2004-06-24 2008-10-30 Eli Lilly And Company Compounds and Methods for Treating Dyslipidemia
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
US7713979B2 (en) 2004-10-29 2010-05-11 Eli Lilly And Company Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EP1893612B1 (en) * 2005-06-22 2011-08-03 Plexxikon, Inc. Pyrrolo [2, 3-b]pyridine derivatives as protein kinase inhibitors
FR2890071B1 (fr) 2005-08-30 2007-11-09 Fournier Sa Sa Lab Nouveaux composes de l'indole
AU2007227681A1 (en) 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
US8026257B2 (en) 2007-07-11 2011-09-27 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
CN101855221B (zh) * 2007-11-15 2013-10-30 P.安杰莱蒂分子生物学研究所 作为parp抑制剂的哒嗪酮衍生物
SG173584A1 (en) 2009-02-06 2011-09-29 Elan Pharm Inc Inhibitors of jun n-terminal kinase
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
CN102762534A (zh) 2009-09-18 2012-10-31 扎里卡斯药品有限公司 作为钙通道阻断剂的芳基砜衍生物
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US8466186B2 (en) * 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
EP2487159A1 (en) * 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
MX336578B (es) 2011-07-25 2016-01-25 Allergan Inc Derivados de n-(imidazolidin-2-ilideno)-heterociclopenta[b] pirididina como moduladores de receptores de alfa 2 adrenergicos.
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
UA111754C2 (uk) * 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
JP6073343B2 (ja) 2011-10-20 2017-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
EP2647628A1 (en) 2012-04-02 2013-10-09 Almirall, S.A. Substituted tricyclic compounds with activity towards ep1 receptors
WO2014026328A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
EP2991994B1 (en) 2013-05-01 2018-08-15 Vitae Pharmaceuticals, Inc. Thiazolopyrrolidine inhibitors of ror-gamma
LT3027603T (lt) * 2013-08-02 2018-08-10 Pfizer Inc. Heterobicikloarilo rorc2 inhibitoriai ir jų panaudojimo būdai
EP3044224A1 (en) 2013-09-11 2016-07-20 F. Hoffmann-La Roche AG KETO-IMIDAZOPYRIDINE DERIVATIVES AS RORc MODULATORS
SG11201606080SA (en) 2014-02-03 2016-08-30 Vitae Pharmaceuticals Inc Dihydropyrrolopyridine inhibitors of ror-gamma
PT3207043T (pt) 2014-10-14 2019-03-25 Vitae Pharmaceuticals Llc Inibidores de di-hidropirrolopiridina de ror-gama
LT3307734T (lt) * 2015-06-09 2020-05-11 Abbvie Inc. Branduolinio receptoriaus moduliatoriai (ror), skirti uždegiminių ir autoimuninių ligų gydymui

Similar Documents

Publication Publication Date Title
JP2018521020A5 (ja)
JP2017008120A5 (ja)
JP2018024670A5 (ja)
JP2012107057A5 (ja)
JP2019194236A5 (ja)
JP2017509667A5 (ja)
JP2018168171A5 (ja)
JP2017186358A5 (ja)
JP2014507446A5 (ja)
JP2019089762A5 (ja)
JP2018150298A5 (ja)
JP2020515557A5 (ja)
JP2014221779A5 (ja)
JP2013532130A5 (ja)
JP2012111758A5 (ja)
JP2014235432A5 (ja)
JP2011510079A5 (ja)
JP2018525542A5 (ja)
JP2015199738A5 (ja)
JP2016535100A5 (ja)
JP2011519871A5 (ja)
JP2016532632A5 (ja)
JP2013532687A5 (ja)
JP2016539168A5 (ja)
JP2018030858A5 (ja)